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Abstract
Background: Aryl hydrocarbon receptor-interacting protein (AIP) is evolutionarily 
conserved and expressed widely throughout the organism. Loss-of-function AIP 
mutations predispose to young-onset pituitary adenomas. AIP co-localizes with growth 
hormone in normal and tumorous somatotroph secretory vesicles. AIP protein is 
detectable in circulation. We aimed to investigate possible AIP and GH co-secretion, by 
studying serum AIP and GH levels at baseline and after GH stimulation or suppression, in 
GH deficiency (GHD) and in acromegaly patients.
Subjects and methods: Insulin tolerance test (ITT) was performed in GHD patients (n = 13) 
and age-BMI-matched normal GH axis control patients (n = 31). Oral glucose tolerance 
test (OGTT) was performed in active acromegaly patients (n = 26) and age-BMI-matched 
normal GH axis control patients (n = 18). In-house immunometric assay was developed 
for measuring circulating AIP.
Results: Serum AIP levels were in the 0.1 ng/mL range independently of gender, age or 
BMI. Baseline AIP did not differ between GHD and non-GHD or between acromegaly and 
patients with no acromegaly. There was no change in peak, trough or area under the 
curve during OGTT or ITT. Serum AIP did not correlate with GH during ITT or OGTT.
Conclusions: Human circulating serum AIP in vivo was assessed by a novel immunometric 
assay. AIP levels were independent of age, sex or BMI and unaffected by hypoglycaemia or 
hyperglycaemia. Despite co-localization in secretory vesicles, AIP and GH did not correlate 
at baseline or during GH stimulation or suppression tests. A platform of reliable serum AIP 
measurement is established for further research of its circulatory source, role and impact.
Introduction
Aryl hydrocarbon receptor-interacting protein (AIP) is a 
molecular co-chaperone to heat-shock proteins. Interest 
in its nature and function originated from the discovery 
that heterozygous loss-of-function AIP mutations 
predispose to pituitary adenomas (PA) (1, 2, 3). AIP protein 
is highly conserved evolutionarily and widely distributed 
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throughout the organism (4). Homozygous Aip deletion 
leads to embryonic lethality in both mammalian and 
invertebrate models (5, 6).
The AIP protein is a 37 kDa, 330 amino-acid member 
of FKBP (FK506-binding protein) family. The highly 
conserved C-terminal TPR motifs mediate many of its 
protein–protein interactions (7, 8, 9). A long half-life of 
AIP suggests its abundance and structural complexity 
(10). AIP was originally discovered as a binding partner 
of aryl hydrocarbon receptor (AhR), which is best known 
for mediating the effects of environmental toxins such 
as dioxin (11, 12, 13). AIP may play diverse biological 
roles through interactions with various other interacting 
partners (14). Some of its interactions involve anti-
oxidative and anti-proliferative pathways or mechanisms 
instrumental in the regulation of cytoskeletal organization 
and integrity of adherens junction (10, 15).
AIP mutations were found in 20% of patients with 
familial isolated pituitary adenoma (FIPA) and in 25% 
of sporadic somatotropinomas of childhood onset (16, 
17). Most often these are invasive GH- or PRL-secreting 
macroadenomas, resistant to somatostatin analogue (SA) 
treatment (17, 18). AIP is thought to play an important 
role in the response to SA in acromegaly (19). Neither 
the exact mechanism of AIP influence on proliferation 
inhibition, nor its possible role in normal pituitary 
function is known.
AIP mRNA was expressed in normal pituitary tissue 
and in sporadic somatotropinomas, prolactinomas, 
corticotropinomas and non-functioning pituitary 
adenoma. In normal pituitary tissue, double-
immunofluorescence staining detected AIP exclusively in 
GH and PRL cells, sub-localized by electron microscopy 
to secretory vesicles. Unlike the normal pituitary, in 
PAs, AIP protein was expressed in somatotropinomas, 
prolactinomas, corticotropinomas and non-functioning 
pituitary adenomas (3). However, subcellular AIP 
distribution depended on the adenoma cell type. Only 
in somatotropinomas was AIP staining detected in 
the secretory vesicles, similarly to normal human GH 
cells and rat pituitary-derived GH3 cells, whereas being 
distributed within the cytoplasm in other PA subtypes (3). 
These findings raised an interest in the question of AIP 
being released from secretory vesicles of somatotrophs 
or lactotrophs.
Several studies demonstrated decrease in basal or 
stimulated GH secretion in non-adenomatous GH3 cells 
after endogenous Aip knockdown or transfection with 
mutated AIP (20, 21). TRIP8b – a protein involved in ACTH 
release – shares similarity in the TPR domain with AIP, 
which added to the interest in a potential corresponding 
role of AIP in GH release (22). Cellular mechanisms 
were identified linking AIP to synaptic vesicles, which 
share many conserved features with endocrine secretory 
vesicles (23).
Many of molecular chaperones and protein-folding 
catalysts can be secreted from cells and function 
additionally as pleiotropic signals for a variety of cells 
principally involved in immunity and inflammation 
(24). Even FKBP family members were also found to be 
secreted into the systemic circulation acting on distant 
cell-surface receptors (25, 26). The presence and dynamic 
responsiveness of AIP protein in human circulation was 
demonstrated by plasma proteomics (27).
All these data gave rise to our hypothesis that AIP 
could be co-secreted with GH. We have aimed to study 
the correlation of constitutive and dynamic AIP and 
GH secretion using in vivo human models of normal GH 
secretion, patients with GH deficiency (GHD) and patients 
with GH hypersecretion – acromegaly.
Subjects and methods
Subjects
A total of 88 adult subjects were divided into four groups 
based on their GH secretion status. Groups consisted 
of patients with GH deficiency – GHD (n = 13), control 
patients with preserved GH secretion (non-GHD, 
NGHD, n = 31), patients with active acromegaly (AA, 
n = 26) and control patients with preserved (normal) 
GH suppressibility (NGHS, n = 18). Demographic and 
anthropometric characteristic of investigated subjects 
are summarized in Table  1. Patients with GHD and 
NGHD were matched for age and BMI. Six of the GHD 
patients had isolated GHD and seven had additional 
pituitary hormone deficiencies, two of which had 
complete anterior pituitary hormone deficiency with 
additional central diabetes insipidus in one of the two. 
The AA and NGHS groups were matched for age, sex 
and BMI. The AA patients (16 with macroadenoma and 
10 with microadenoma) were either newly diagnosed 
or persistent after treatment. Seven patients have 
previously received somatostatin analogue treatment; 
none at the time of testing. One had previously received 
dopamine agonists. In the NGHS group, 12 patients 
with acromegaly were cured by surgery and six subjects 
had non-functioning pituitary adenomas with normal 
GH dynamics.
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GHD was defined by the GH peak in insulin tolerance 
test (ITT) <3.0 ng/mL or in the presence of multiple 
pituitary hormone deficiencies and IGF-1 below the 
age- and population-specific reference range. Preserved 
GH axis was defined by peak GH in ITT >5 ng/mL 
following a blood glucose nadir of ≤2.2 mmol/L (28). 
Active acromegaly was defined in the presence of 
clinical manifestations, unsuppressible GH in oral 
glucose tolerance test (OGTT, nadir >1.0 ng/mL) and 
elevated IGF-1 (above age-related reference range). Active 
acromegaly was excluded by suppressible GH in OGTT 
<1.0 ng/mL (29). All subjects were assessed by a physical 
examination and routine biochemical analysis of serum 
and urine. Subjects with severe renal insufficiency (eGFR 
<30 mL/min) were excluded. All patients were informed 
in detail of the study procedures and their written consent 
was obtained in accordance to the study approval by the 
Ethics Committee of Belgrade University Medical Faculty 
(Approval No 29/XII-23). The research was conducted 
at the Department for Neuroendocrinology, Clinic for 
Endocrinology, Clinical Centre of Serbia, from July 2014 
to December 2015.
Dynamic tests of GH secretion
ITT was performed after excluding contraindications 
(history or risk of seizures or coronary heart disease) by 
standard departmental procedure: after an i.v. bolus of 
Actrapid-Insulin 0.15 IU/kg, cubital vein blood samples 
were taken via i.v. cannula at 0, 30, 60, 90 and 120 min 
for serum analysis of GH, PRL, cortisol and AIP. Tests were 
initiated at 8:00 h in a supine position after overnight rest 
and fasting.
OGTT was performed after excluding contraindications 
(diabetes mellitus) by standard departmental procedure 
with oral application of 75 g glucose solution at 8:00 h 
after an overnight fasting and resting, followed by cubital 
vein blood sampling for GH and AIP analysis via i.v. 
cannula at 0, 30, 60, 90 and 120 min after glucose load.
Hormonal analysis
All serum samples were stored at −80°C until analysed 
for GH, cortisol and PRL at the Clinic for Endocrinology, 
Diabetes and Metabolic Diseases, Clinical Centre of Serbia. 
GH was measured by immunoradiometric assay HGH-RIA 
CT Cisbio Bioassays, Codolet, France (Calibrator WHO IS 
98/574; limit of detection (LOD) 0.01 ng/mL within-run 
coefficients of variation (CV) 2.1% (for mean 1.4 ng/mL) 
and 1.3% (for mean 21.0 ng/mL) between-run CV 4.5% (for 
mean 1.3 ng/mL) 5.0% (for mean 5.9 ng/mL) 3.8% (for mean 
8.1 ng/mL) and 4.8% (for mean 12.4 ng/mL). Cortisol was 
measured by CORT-CT2 Cisbio Bioassays, Codolet, France 
(intra-assay CV 5.3% (for mean 64 nmol/L) 3.6% (for mean 
251 nmol/L) 3.7% (for mean 686 nmol/L); inter-assay CV 
5.7% (for mean 63 nmol/L), 8.1% (for mean 222 nmol/L) 
and 6.7% (for mean 565 nmol/L) LOD 6.6 nmol/L). 
Prolactin was measured by immunoradiometric assay 
PRL-IRMA DIAsource ImmunoAssays, Louvain-la-Neuve, 
Belgium ((intra-assay CV 3.3% (for mean 7.5 ng/mL), 5.2% 
(for mean 26.6 ng/mL); inter-assay CV 9.2% (for mean 
7.4 ng/mL) and 4.5% (for mean 49.1 ng/mL)). IGF-1 was 
measured using Siemens Immulite 2000 assay (calibrator 
WHO IS 87/518), LOD 20 ng/mL, highest measurable value 
1600 ng/mL, intra-assay CV 3.9% at 77 ng/mL, 6.5% at 
169 ng/mL, 2.9% at 380 ng/mL, 3.0% at 689 ng/mL, 2.3% 
at 1053 ng/mL, 2.4% at 1358 ng/mL; inter-assay CV 7.7% at 
77 ng/mL, 5.4% at 169 ng/mL, 7.4% at 380 ng/mL, 8.1% at 
689 ng/mL, 3.7% at 1053 ng/mL and 4.7% at 1358 ng/mL.
Circulating AIP analysis
All serum samples were stored at −80°C until transported 
under secured temperature conditions for analysis performed 
at Department of Medicine for Endocrinology, Diabetes 
and Nutritional Medicine, Charité Universitätsmedizin, 
Campus Mitte, Berlin, Germany. All samples were uniformly 
analysed in a single batch by an in-house AIP assay. The 
LOD of the AIP assay was 0.068 ng/mL. The intra-assay CVs 
were 3.1–4.9%; inter-assay CVs were 8.2–13.5%.
Table 1 Demographic and anthropometric characteristics of investigated subjects.
Group
P value
Group
P valueGHD NGHD AA NGHS
N 13 31 26 18
Age (years) 38.8 ± 3.76 35.1 ± 2.42 0.406a 50.4 ± 2.65 51.0 ± 2.60 0.882a
Gender (female) 5 (38.5%) 22 (71.0%) 0.043b 17 (65.4%) 11 (61.1%) 0.772b
BMI (kg/m2) 27.37 ± 1.54 26.18 ± 1.54 0.641a 27.85 ± 0.78 29.13 ± 1.52 0.461a
Data are expressed as mean and s.e. (age and BMI) or as % (gender).
at-test; bChi-square test.
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Production and purification of monoclonal and 
polyclonal antibodies against AIP
Two-month-old female Balb/c mice were immunized with 
recombinant human AIP (produced in E. coli) dissolved 
in TiterMax adjuvant and injected intradermally 
(10 µg antigen/mouse). After 3–6  months of repeated 
immunization, the mice with the highest serum titres 
were killed and spleen cells were fused with NSO cells in 
the presence of polyethylene glycol using the hybridoma 
technique. Cells were grown in medium containing 20% 
horse serum. Hybridoma cell supernatants were screened 
for anti-AIP activity after 10–12  days of culture using 
biotinylated AIP. Hybridoma cells corresponding to the 
highest signals of supernatants were cloned at least twice 
by limiting dilution. The IgG subclass of the monoclonal 
antibodies was determined. Large-scale production was 
carried out in protein-free medium. The polyclonal anti-
AIP antiserum was produced in rabbit immunized with 
recombinant AIP by the service of Davids Biotechnologie 
(Regensburg, Germany). The antibodies were affinity 
purified using an r-Protein A column and FPLC equipment. 
The pooled IgG-containing fractions were extensively 
dialyzed against PBS, divided into aliquots and stored at 
−20°C until use.
Biotinylation of monoclonal antibodies and AIP
The purified monoclonal antibodies were biotinylated 
using a 75-fold molecular excess of the labelling reagent 
(biotinamidocaproate-N-hydroxysuccinimide ester) in 
the reaction. AIP was biotinylated using the same method 
but with 25-fold molar excess of biotin.
Assay standards
The recombinant AIP diluted in assay buffer was used as 
the calibrator for the sandwich assay. To minimize matrix 
differences between serum samples and calibrators, 
additional BSA was added to the calibrators (final protein 
concentration 7%).
Time-resolved fluorescence sandwich immunoassay 
for AIP
To increase AIP assay sensitivity for detection of all AIP 
molecules (including possible differently glycosylated 
forms), a sandwich assay was constructed with 
polyclonal and monoclonal antibodies combination. 
Microtitre plates were coated with polyclonal AIP 
antibodies (250 ng/well) diluted in phosphate buffer 
(50 mmol/L, pH 7.4) by overnight incubation at 4°C. 
Detection antibodies were diluted in assay buffer 
(50 mmol/L Tris-(hydroxymethyl)-aminomethane, 
154 mmol/L NaCl, 20 mol/L diethylenetriaminepenta-
acetic acid, 0.01% Tween 40 and 0.05% NaN3 (pH 7.75)) 
BSA (0.5%) and bovine-globulin (0.05%) were added 
to reduce nonspecific binding. Washing buffer was 
prepared freshly for all experiments (PBS and 0.05% 
Tween 20). The coated microtitre plates were washed, 
25 µL standards or samples were pipetted into each well 
together with 12.5 ng biotinylated anti-AIP monoclonal 
antibody 1A11 and 12.5 ng biotinylated anti-AIP 
monoclonal antibody 3E1 in 75 µL assay buffer. After 
an overnight incubation at 4°C, the microtitre plates 
were washed three times with 0.3 mL wash buffer, 
and 10 ng europium-labelled streptavidin was added 
into each well and incubated (60 min). After a six-fold 
washing step, the addition of 0.2 mL enhancement 
solution to each well, and a final incubation (10 min) 
on a horizontal plate shaker, the signal was read using 
the Victor multilabel counter.
Statistical analysis
Hormone concentrations were analysed as baseline values, 
and GH, cortisol and PRL peaks during ITT, nadir GH in 
OGTT, GH-, cortisol- and PRL-area under the curve0–120min 
(AUC0–120min) in ITT and GH-AUC0–120min in OGTT. Results 
are presented as count (%), mean ± standard error or 
median (25th–75th percentile) depending on data type 
and distribution. AIP values were expressed as median 
and interquartile range (25th and 75th percentile) of 
original non-normalized values. Serum AIP values were 
analysed as baseline, maximal and minimal values of AIP 
the dynamic tests, AIP AUC0–120min during the test and AIP 
Delta increment during test which was calculated as AIP 
Delta = (AIPmax − AIPbaseline)/AIPbaseline. Integrated 
areas of secretion (AUC0–120min) were calculated using the 
trapezoidal method.
Normality of variable distribution was tested using 
the Kolmogorov–Smirnov and Shapiro–Wilk tests. 
Non-normally distributed variables were transformed 
using logarithmic transformation (log10). Groups were 
compared for significance of difference using parametric 
(t-test) and nonparametric (chi-square, Mann–Whitney U 
and Friedman) tests. To assess significance of correlation 
between variables, Spearman correlation was used. 
Friedman test was used to evaluate a significance of change 
between serum AIP values in different time points of the 
conducted tests (ITT and OGTT). SPSS Statistics, version 
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22 software was employed for the statistical analyses. 
P values of <0.05 were regarded as indicating statistical 
significance.
Results
Hormone responses to ITT and OGTT
GH peak in ITT was significantly lower in the GHD 
group compared to NGHD group: 1.42 ± 0.22 ng/mL 
vs 15.09 ± 6.26 ng/mL (P < 0.01). PRL peak in ITT was 
significantly lower in the GHD group compared to 
NGHD group: 26.76 ± 3.69 ng/mL vs 114.59 ± 14.17 ng/mL 
(P < 0.01). Cortisol peak in ITT was not significantly 
different in the GHD group compared to NGHD group: 
710.0 ± 51.3 ng/mL vs 636.9 ± 23.6 ng/mL (P = 0.21).
Nadir GH in OGTT was significantly lower in the 
NGHS than in the AA group: 0.29 ± 0.05 ng/mL vs 
11.27 ± 2.90 ng/mL (P < 0.01).
AIP concentrations in serum
Impact of gender, age and BMI on serum AIP
Baseline AIP, AIP max, AIP AUC and AIP Delta did not 
differ significantly between genders in either group 
(Supplementary Table 1, see section on supplementary data 
given at the end of this article). Baseline AIP, AIP max, AIP 
AUC and AIP Delta did not correlate significantly with age 
in either group (Supplementary Table 2). Baseline AIP, AIP 
max, AIP AUC and AIP Delta did not correlate significantly 
with BMI in either group (Table 2).
Impact of normal GH secretion on serum AIP
Baseline AIP, AIP max, AIP AUC and AIP Delta did not 
differ significantly between the GHD and NGHD group 
(Fig. 1 and Supplementary Table 3). Baseline AIP, AIP max, 
AIP AUC and AIP Delta did not differ significantly between 
the AA and NGHS groups (Fig.  2 and Supplementary 
Table 4).
Serum AIP during dynamic testing
There was no difference in AIP values at 0, 30, 60, 90 and 
120 min of the ITT in the GHD or NGHD groups nor in all 
ITT-tested subjects combined (n = 44) (Fig.  3 and Table  3). 
There was no difference in AIP values at 0, 30, 60, 90 and 
120 min of the OGTT in the AA or NGHS groups nor in all 
OGTT-tested subjects combined (n = 44) (Fig. 4 and Table 4).
Correlation of AIP with pituitary hormones during 
dynamic tests
Baseline AIP did not correlate significantly with baseline GH, 
PRL or cortisol in the GHD or NGHD groups. AIPmax did not 
Table 2 Correlation of baseline and dynamic AIP values with BMI.
Baseline AIP (ng/mL) BMI (kg/m2) R P
GHD 0.155 (0.112–0.326) 27.37 ± 1.54 −0.275 0.363
NGHD 0.143 (0.087–0.339) 26.18 ± 1.54 −0.062 0.751
AA 0.096 (0.067–0.159) 29.13 ± 1.52 0.115 0.628
NGHS 0.153 (0.068–0.302) 29.13 ± 1.52 −0.448 0.072
AIPmax (ng/mL) BMI (kg/m2) R P
GHD 0.292 (0.160–0.587) 27.37 ± 1.54 0.074 0.809
NGHD 0.278 (0.146–0.562) 26.18 ± 1.54 0.019 0.920
AA 0.190 (0.106–0.247) 29.13 ± 1.52 −0.045 0.850
NGHS 0.190 (0.132–0.415) 29.13 ± 1.52 −0.282 0.273
AIP AUC (ng/mL/120 min) BMI (kg/m2) R P
GHD 25.90 (13.03–50.03) 27.37 ± 1.54 0.044 0.886
NGHD 24.58 (13.32–46.46) 26.18 ± 1.54 0.025 0.898
AA 12.85 (9.97–22.16) 29.13 ± 1.52 0.085 0.721
NGHS 16.63 (10.46–26.00) 29.13 ± 1.52 −0.350 0.168
AIP Delta BMI (kg/m2) R P
GHD 0.43 (0.03–0.90) 27.37 ± 1.54 0.210 0.491
NGHD 0.69 (0.23–1.32) 26.18 ± 1.54 0.026 0.895
AA 0.38 (0.00–0.74) 29.13 ± 1.52 −0.007 0.977
NGHS 0.14 (0.00–0.59) 29.13 ± 1.52 0.338 0.185
Data are expressed as median and interquartile range (AIP values) or as mean and s.e. (BMI values).
R, Spearman’s Rho.
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correlate significantly with GHmax, PRLmax or cortisol peak 
in the GHD or NGHD groups. AIP AUC did not correlate 
significantly with GH, PRL or cortisol AUC in the GHD or 
NGHD groups (Tables 5, 6 and Supplementary Tables 5, 6).
Discussion
We set out to measure circulating AIP, as previous data 
suggested its localization within the secretory vesicles of 
somatotrophs in both normal and adenomatous pituitary. 
Using a novel immunometric assay, circulating serum AIP 
Figure 1
(A) Maximal AIP value in ITT (ng/mL, log scale) in GH deficiency (GHD) vs 
non-GHD (NGHD) patients. (B) AIP AUC in ITT (ng/mL/120 min, log scale) in 
GHD vs NGHD patients. (C) Delta AIP in ITT (log scale) in GHD vs NGHD 
patients.
Figure 2
(A) Maximal AIP value during OGTT (ng/mL, log scale) in active acromegaly 
(AA) vs normal GH suppression (NGHS) patients. (B) AIP AUC in OGTT 
(ng/mL/120 min, log scale) in AA vs NGHS patients. (C) Delta AIP in OGTT 
(log scale) in AA vs NGHS patients.
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levels were successfully and reliably measured during 
a five-point dynamic endocrine test in all 88 studied 
patients, in the 0.1 ng/mL range. Baseline serum AIP was 
independent of age, gender or BMI. Serum AIP levels in 
all investigated groups were stable over time in samples 
taken at 30-min intervals over 2-h course and were 
unchanged by severe hypoglycaemia (induced by ITT) 
or hyperglycaemia (induced by OGTT). Despite apparent 
AIP and GH co-localization in somatotroph secretory 
vesicles upon electromicroscopy and double fluorescence 
immunostaining (3), results of this study demonstrated 
that serum AIP concentrations are independent of GH 
elevation (baseline or during ITT) or suppression (baseline 
or during OGTT). No difference was observed in AIP levels 
(basal, maximal or integrated) between subjects with GH 
deficiency (GHD) or preserved GH secretion, nor between 
the subjects with active acromegaly (unsuppressibly 
elevated GH) versus those with normal GH suppressibility. 
Neither did serum AIP and GH correlate at baseline, nor 
during ITT or OGTT. Our results directly demonstrate 
that serum AIP is stable over time in human circulation 
despite significant oscillations in blood glucose, with no 
effect from severe hypoglycaemia or hyperglycaemia, a 
significant rise in GH, cortisol, PRL (directly) or ACTH 
(indirectly based on its physiological response to ITT).
Previous findings on plasma AIP, determined by 
the novel proteomics technology SOMAmer, indicated 
a significant increase in AIP levels following a high-
fat meal (three-fold rise from baseline over 6 h) in diet-
resistant obese subjects (27). Our results in individuals 
with an average BMI of 28.4 ± 0.8 kg/m2 (all 44 OGTT-
tested subjects) indicate no change in serum AIP over 2 h 
following oral glucose load.
While the exact role of AIP in pituitary adenoma 
tumorigenesis is being intensively investigated, little 
is known about its role in normal pituitary function. 
Several molecular chaperones, in addition to their 
intracellular roles, were shown to be secreted from cells 
and function as distant mediators involved in immunity 
or inflammation (24). AIP is expressed in numerous 
tissues, but its subcellular localization to secretory vesicles 
was demonstrated only in pituitary somatotrophs and 
lactotrophs (3).
We considered several hypotheses to explain the 
observed divergence between previously demonstrated 
secretory vesicle co-localization of AIP and GH and 
absent co-secretion detectable in the systemic circulation. 
Previous examples related to pituitary and other 
endocrine cells provide possible paradigms mirroring our 
findings (30, 31, 32, 33, 34, 35, 36). FSH and LH are both 
released from the same gonadotroph cells but differ in 
dynamic responses throughout the menstrual cycle (30, 
33). This is explained by the distinct hormonal content 
(either FSH and LH alone or both) of the secretory vesicles 
subtypes, secretory granin content and proximity to the 
membrane surface (30, 33). Secretoneurin, a secretogranin 
derivate, was demonstrated by electron microscopy as 
co-stored with GH in secretory vesicles and constitutively 
secreted from retinal ganglion cells, but unlike GH 
lacking a stimulatory response to GHRH in vitro (32). 
Figure 3
Serum AIP (ng/mL, log scale) in 0, 30, 60, 90 and 120 min of ITT (all 44 
tested subjects).
Table 3 AIP values at baseline and during ITT.
GHD (n = 13) NGHD (n = 31) All (n = 44)
AIP0min (ng/mL) 0.155 (0.129–0.203) 0.143 (0.087–0.339) 0.149 (0.097–0.332)
AIP30min (ng/mL) 0.140 (0.99–0.385) 0.210 (0.128–0.341) 0.204 (0.120–0.367)
AIP60min (ng/mL) 0.198 (0.127–0.299) 0.245 (0.119–0.382) 0.214 (0.121–0.377)
AIP90min (ng/mL) 0.192 (0.084–0.331) 0.173 (0.103–0.511) 0.181 (0.096–0.397)
AIP120min (ng/mL) 0.155 (0.133–0.405) 0.160 (0.088–0.375) 0.158 (0.105–0.398)
Pa 0.962 0.174 0.293
Data are expressed as median and interquartile range.
aFriedman test.
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Galanin, a modulatory neuropeptide, was co-localized 
within healthy and adenomatous human corticotrophs 
and rodent lactotrophs, somatotrophs and thyrotrophs. 
In vitro GH and galanin were secreted from mutated rat 
pituitary cells. However, co-secretion of galanin and 
anterior pituitary hormones was absent, attributable 
either to their release under different stimuli or a limited 
contribution of pituitary secretion to overall circulating 
galanin (34, 35).
Given the ubiquitous nature of AIP expression, the 
contribution of pituitary-origin AIP to circulating AIP 
might be negligible. The presence of measurable serum 
AIP similar to the cohort’s average even in our two 
patients with complete anterior pituitary deficiency (one 
with additional posterior pituitary deficiency) supports 
this possible explanation. Data from studies screening 
all human organs confirmed AIP mRNA expression in 
36 studied tissues (37). We have recently identified a 
role of AIP in lymphocytes, which could be a source of 
circulating AIP (38). A close correlation between AIP 
and GH levels may not be expected due to their highly 
discrepant half-lives, being in the order of 30 h for AIP 
compared to only 16 min for GH (10). The long half-life 
of AIP advocates that it should be measurable peripherally 
as well as centrally. However, petrosal venous sampling 
with central to peripheral gradient analysis could better 
confirm or refute pituitary as the source of circulating AIP.
AIP might have a predominantly autocrine or 
paracrine effect (perhaps on GH secretion modulation) 
and the measurable circulating levels might purely 
result from cell death or damage-related leakage rather 
than a regulated secretory event. AIP does lack some 
of the typical secreted peptide characteristics, such as a 
signal peptide or glycosylation sites. However, there are 
several other compounds known to be secreted without 
glycosylation sites (e.g. ferritin) or without signal peptides 
(e.g. FGF1 or IL-6) including members of the same 
immunophilin family that AIP belongs to, such as FKBPL 
and cyclophilin A (25, 39). In endocrine cells, co-secreted 
molecules which are not part of the main prohormone 
are usually produced in amounts 100–1000-fold smaller 
than the main secreted product, baring largely autocrine 
or paracrine actions. However, the circulatory serum AIP 
concentrations measured in our study were consistently 
of the same order of magnitude as the circulatory GH.
GH stimulation during ITT is predominantly mediated 
at the supra-hypothalamic level resulting in GHRH release 
and somatostatin inhibition, with a smaller effect directly 
at the pituitary level (40). Other GH secretagogues, 
such as ghrelin could, theoretically, be missed by using 
hypoglycaemia as a test stimulus and this could have 
an effect on AIP release. In addition, the well-described 
heterogeneity of GH cell subpopulations with different 
susceptibility to releasing stimulants could perhaps result 
in discrepant co-secretion (41).
The first recognized partner of AIP is the nuclear 
receptor AhR, known to bind environmental toxins. The 
role of the AhR-AIP pathway has been studied in pituitary 
cells and patients with acromegaly (42, 43, 44, 45, 46, 
47, 48). Several in vitro studies have related exposure to 
AhR-mediated toxins in GH3 cells to an increase in either 
proliferation (47) or GH secretion (48). An epidemiological 
Figure 4
Serum AIP (ng/mL, log scale) in 0, 30, 60, 90 and 120 min of OGTT (all 44 
tested subjects).
Table 4 AIP values at baseline and during OGTT.
AA (n = 26) NGHS (n = 18) All (n = 44)
AIP0min (ng/mL) 0.097 (0.068–0.151) 0.153 (0.069–0.293) 0.108 (0.068–0.204)
AIP30min (ng/mL) 0.110 (0.069–0.184) 0.148 (0.068–0.224) 0.120 (0.068–0.178)
AIP60min (ng/mL) 0.076 (0.068–0.189) 0.125 (0.102–0.145) 0.096 (0.068–0.178)
AIP90min (ng/mL) 0.105 (0.084–0.197) 0.127 (0.068–0.190) 0.121 (0.068–0.196)
AIP120min (ng/mL) 0.104 (0.068–0.155) 0.126 (0.068–0.361) 0.114 (0.068–0.175)
Pa 0.118 0.152 0.188
Data are expressed as median and interquartile range.
aFriedman test.
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association was proposed between exposition to 
environmental pollution and somatotropinoma incidence 
(43), although no direct link was found in the area with 
an inductrial accident involving dioxin (42). AHR and AIP 
genetic variants were studied in acromegaly patients to 
investigate whether they have a modifying effect together 
with pollution exposure on adenoma size, biochemical 
severity and resistance to somatostatin analogues (45). 
Individual history of exposure to xenobiotics might also 
influence the secretory response of AIP. We have not 
collected these data on our pituitary patients in this study. 
It is conceivable that the degree of AhR involvement in 
detoxification could impact intracellular AIP distribution, 
and consequently its secretion. Circulating human AIP 
analysis might find potential application in the expanding 
field of endocrine disruptor chemicals research.
Our results leave open the question of the physiological 
significance of circulating AIP, but provide a solid platform 
of a reliable in vivo human circulatory serum AIP protein 
immunometric assay measurement to be used for further 
research. The independence of circulating AIP levels 
from age, gender and BMI and considerable circulatory 
stability and autonomy from severe hypoglycaemia or 
hyperglycaemia are demonstrated, as well as independence 
from the GH, PRL and cortisol secretory dynamics in ITT 
and from GH secretory dynamics in OGTT.
Conclusion
Serum levels of AIP were reliably measured in the 
circulation by a novel immunometric assay. Serum AIP 
levels are found to be independent of age, sex or BMI and 
unaffected by hypoglycaemia or hyperglycaemia. A rise in 
serum GH, ACTH and cortisol or PRL is not accompanied by 
serum AIP concentration change. Contrary to expectations 
based on secretory vesicles co-localization studies, neither 
constitutive nor stimulated co-secretion of AIP and GH 
Table 5 Correlation of baseline and dynamic AIP and GH values in ITT.
Baseline AIP (ng/mL) Baseline GH (ng/mL) R P
GHD 0.155 (0.112–0.326) 0.28 ± 0.06 0.121 0.694
NGHD 0.143 (0.087–0.339) 0.45 ± 0.11 0.440 0.816
AIPmax (ng/mL) GH max (ng/mL) R P
GHD 0.292 (0.160–0.587) 1.42 ± 0.22 0.385 0.194
NGHD 0.278 (0.146–0.562) 15.09 ± 1.12 0.008 0.967
AIP AUC (ng/mL/120 min) GH AUC (ng/mL/120 min) R P
GHD 25.90 (13.03–50.03) 89.78 ± 13.82 0.462 0.112
NGHD 24.58 (13.32–46.46) 952.44 ± 78.15 0.198 0.286
Data are expressed as median and interquartile range (AIP values) or as mean and s.e. (GH values).
R, Spearman’s Rho.
Table 6 Correlation of baseline and dynamic AIP and GH values in OGTT.
Baseline AIP (ng/mL) Baseline GH (ng/mL) R P
AA 0.096 (0.067–0.159) 14.73 ± 3.25 0.061 0.768
NGHS 0.153 (0.068–0.302) 0.56 ± 0.08 0.204 0.416
Baseline AIP (ng/mL) Nadir GH (ng/mL) R P
AA 0.096 (0.067–0.159) 11.27 ± 2.90 0.079 0.702
NGHS 0.153 (0.068–0.302) 0.29 ± 0.05 0.140 0.580
AIPmax (ng/mL) GH max (ng/mL) R P
AA 0.190 (0.106–0.247) 17.23 ± 3.46 0.195 0.340
NGHS 0.190 (0.132–0.415) 0.82 ± 0.18 0.087 0.731
AIP AUC (ng/mL/120 min) GH AUC (ng/mL/120 min) R P
AA 12.85 (9.97–22.16) 1692.46 ± 378.23 0.263 0.194
NGHS 16.63 (10.46–26.00) 52.57 ± 7.71 0.176 0.484
AIP AUC (ng/mL/120 min) Nadir GH (ng/mL) R P
AA 12.85 (9.97–22.16) 11.27 ± 2.90 0.273 0.178
NGHS 16.63 (10.46–26.00) 0.29 ± 0.05 0.141 0.577
Data are expressed as median and interquartile range (AIP values) or as mean and s.e. (GH values).
R, Spearman’s Rho.
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is observed. As this conserved protein is necessary for 
survival, a platform of reliable immunometric serum AIP 
measurement is key for further research of its circulatory 
source, role and impact.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0082.
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